Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + SOX in resectable gastric cancer
NCT04982939Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Pathological Complete Response Rate. Status: unknown.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04982939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982939.